Source 1primary paper2025MED
Toolkit/Synergistic Activation Mediator (SAM) CRISPRa system
Synergistic Activation Mediator (SAM) CRISPRa system
Also known as: SAM, SAM-based CRISPRa
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
We demonstrate the toxicity of CRISPRa vectors expressing the activation domains (ADs) of the transcription factors p65 and HSF1, components of the synergistic activation mediator (SAM) CRISPRa system.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Evaluate cytotoxicity and practical deployability of potent CRISPRa activator architectures, especially SAM-associated activators, across lentiviral production and target-cell expression contexts.
Why it works: The study compares activator expression consequences in producer cells and transduced target cells, then tests inducible expression to determine whether effective activation can be separated from toxicity.
transcriptional activation by potent activator domainstoxicity associated with activator expressionlentiviral vector expressioninducible lentiviral expression
Stages
- 1.Initial toxicity assessment of SAM-associated activators(functional_characterization)
The study begins with SAM to establish whether a widely used potent CRISPRa architecture has toxicity liabilities.
Selection: Determine whether p65 and HSF1 activation-domain-containing CRISPRa vectors exhibit toxicity.
- 2.Extension to additional activation domains and acetyltransferase core domains(secondary_characterization)
The paper extends beyond SAM to determine whether toxicity is a broader issue for potent CRISPRa activators.
Selection: Test whether toxicity observations from SAM generalize to other potent activator architectures.
- 3.Producer-cell impact assessment during lentiviral production(functional_characterization)
Producer-cell toxicity or burden can prevent practical deployment even if an activator is potent.
Selection: Measure whether activator expression in lentiviral producer cells reduces lentiviral titers.
- 4.Target-cell toxicity assessment after transduction(confirmatory_validation)
A CRISPRa system must remain tolerable in target cells after delivery to be useful in research or screening.
Selection: Determine whether activator expression in transduced target cells causes cell death.
- 5.Inducible-expression window test for SAM(decision_gate)
Inducible control is used as a practical mitigation strategy to search for a usable expression window.
Selection: Test whether inducible lentiviral control can separate effective SAM-based CRISPRa from measurable toxicity.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
transcriptional activationTarget processes
editingrecombinationselectiontranscriptionValidation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
mixedMammalian Cell Lineapplication demo
Inferred from claim c3 during normalization. Expression of potent transcriptional activators in lentiviral producer cells can lead to low lentiviral titers. Derived from claim c3.
Source:
failedMammalian Cell Linefailed attempt
Inferred from claim c4 during normalization. Expression of potent transcriptional activators in transduced target cells can lead to cell death. Derived from claim c4.
Source:
Supporting Sources
Ranked Claims
Expression of potent transcriptional activators in transduced target cells can lead to cell death.
Further development of CRISPRa technology should consider both gene activation efficiency and activator toxicity.
Expression of potent transcriptional activators in lentiviral producer cells can lead to low lentiviral titers.
Inducible lentiviral vectors did not reveal an activator expression window for effective SAM-based CRISPRa without measurable toxicity.
Toxicity of current SAM-based CRISPRa systems can introduce selection pressures that may confound genetic screens.
Commonly used CRISPRa systems can exhibit pronounced cytotoxicity.
CRISPRa vectors expressing p65 and HSF1 activation domains are toxic.
Approval Evidence
1 source6 linked approval claimsfirst-pass slug synergistic-activation-mediator-sam-crispra-system
We demonstrate the toxicity of CRISPRa vectors expressing the activation domains (ADs) of the transcription factors p65 and HSF1, components of the synergistic activation mediator (SAM) CRISPRa system.
Source:
cell viability effectsupports
Expression of potent transcriptional activators in transduced target cells can lead to cell death.
Source:
design considerationsupports
Further development of CRISPRa technology should consider both gene activation efficiency and activator toxicity.
Source:
manufacturing constraintsupports
Expression of potent transcriptional activators in lentiviral producer cells can lead to low lentiviral titers.
Source:
optimization failuresupports
Inducible lentiviral vectors did not reveal an activator expression window for effective SAM-based CRISPRa without measurable toxicity.
Source:
screening confoundsupports
Toxicity of current SAM-based CRISPRa systems can introduce selection pressures that may confound genetic screens.
Source:
toxicitysupports
Commonly used CRISPRa systems can exhibit pronounced cytotoxicity.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.